Risk-benefit of HMG-CoA reductase inhibitors in the treatment of HIV protease inhibitor-related hyperlipidaemia

ISSN： 1474-0338

Source： Expert Opinion on Drug Safety, Vol.1, Iss.1, 2002-05, pp. : 5-17

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A Risk-Benefit Assessment of HIV Protease Inhibitors

By Moyle G.J. Gazzard B.G.

Drug Safety, Vol. 20, Iss. 4, 1999-04 ,pp. : 299-321

Adis International

Access to resources Recommend Favorite

HMG-CoA Reductase Inhibitors in Chronic Heart Failure: Potential Mechanisms of Benefit and Risk

By Laufs Ulrich Custodis Florian Böhm Michael

Drugs, Vol. 66, Iss. 2, 2006-01 ,pp. : 145-154

Adis International

Access to resources Recommend Favorite

Safety Profiles for the HMG-CoA Reductase Inhibitors: Treatment and Trust

By Davidson M.H.

Drugs, Vol. 61, Iss. 2, 2001-01 ,pp. : 197-206

Adis International

Access to resources Recommend Favorite

The Effects of HMG-CoA Reductase Inhibitors on Endothelial Function

By Tesfamariam Belay

American Journal of Cardiovascular Drugs, Vol. 6, Iss. 2, 2006-01 ,pp. : 115-120

Adis International

Access to resources Recommend Favorite

HMG-CoA Reductase Inhibitors in the Prevention of Stroke

By van Mil A.H.M.

Drugs, Vol. 59, Iss. 1, 2000-01 ,pp. : 1-6

Adis International

Access to resources Recommend Favorite